Filing Analysis
💸 Securities Offering
Filed May 28, 2026
⚪ LOW
Polaryx Therapeutics entered into a Securities Purchase Agreement on May 27, 2026, to raise $10 million in gross proceeds through a private placement of 2,502,696 shares of common stock.
📋 Key Facts
- Gross proceeds: $10 million
- Shares issued: 2,502,696 shares of common stock
- Weighted average price per share: approximately $4.00
- Price range: $3.70 to $4.10 per share based on commitment level
- Dilution: Approximately 5.3% of outstanding shares prior to the placement
- Largest stockholder, MStone Partners Healthcare Limited, participated with a purchase of 88,453 shares for $360,000
- Use of proceeds: Funding the Phase 2 SOTERIA (PLX-200-600) proof-of-concept basket trial, working capital, and general corporate purposes
- Closing date: May 28, 2026
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.